ES2114817B1 - Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas. - Google Patents

Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas.

Info

Publication number
ES2114817B1
ES2114817B1 ES09601091A ES9601091A ES2114817B1 ES 2114817 B1 ES2114817 B1 ES 2114817B1 ES 09601091 A ES09601091 A ES 09601091A ES 9601091 A ES9601091 A ES 9601091A ES 2114817 B1 ES2114817 B1 ES 2114817B1
Authority
ES
Spain
Prior art keywords
association
prevention
cell death
pharmacological
levulosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09601091A
Other languages
English (en)
Other versions
ES2114817A1 (es
Inventor
Jose Maria Estrela
Antonio Esteras
Leonidas Bruseghini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon SA
Original Assignee
Zambon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09601091A priority Critical patent/ES2114817B1/es
Application filed by Zambon SA filed Critical Zambon SA
Priority to EP97920756A priority patent/EP0839534B1/en
Priority to PCT/ES1997/000122 priority patent/WO1997042961A1/es
Priority to DE69714821T priority patent/DE69714821T2/de
Priority to AT97920756T priority patent/ATE222496T1/de
Priority to PT97920756T priority patent/PT839534E/pt
Priority to DK97920756T priority patent/DK0839534T3/da
Priority to US09/007,071 priority patent/US5962421A/en
Publication of ES2114817A1 publication Critical patent/ES2114817A1/es
Application granted granted Critical
Publication of ES2114817B1 publication Critical patent/ES2114817B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ASOCIACION FARMACOLOGICA ENTRE N-ACETILCISTEINA Y LEVULOSA PARA LA PREVENCION DE LA MUERTE CELULAR Y ENFERMEDADES ASOCIADAS. CUANDO LA APLICACION DE LOS MENCIONADOS PRODUCTOS SE HACE SIMULTANEAMENTE SE PRODUCE UN CLARO EFECTO SINERGICO PROTECTOR DE LAS CELULAS PREVINIENDO LA MUERTE CELULAR PRODUCIDA POR DIFERENTES TIPOS DE AGRESIONES RELACIONADAS CON EL STRESS OXIDATIVO. LA RELACION PREFERENTE ENTRE LOS COMPUESTOS DE LA ASOCIACION ES DE LEVULOSA/NAC= 4/1. LA ASOCIACION FARMACOLOGICA SE USA PARA EL TRATAMIENTO DE DIVERSAS CLINICAS, COMO POR EJEMPLO: RINOFARINGITIS Y BRONQUITIS, HEPATOPATIAS AGUDAS Y CRONICAS, INMUNODEFICIENCIAS, INFARTO DE MIOCARDIO, ARTERIOESCLEROSIS, ALZHEIMER, RETINITIS, IMPOTENCIA SEXUAL, NEFRITIS, DERMATITIS Y CAQUEXIA TUMORAL.
ES09601091A 1996-05-16 1996-05-16 Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas. Expired - Fee Related ES2114817B1 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ES09601091A ES2114817B1 (es) 1996-05-16 1996-05-16 Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas.
PCT/ES1997/000122 WO1997042961A1 (es) 1996-05-16 1997-05-13 Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas
DE69714821T DE69714821T2 (de) 1996-05-16 1997-05-13 Pharmakologische kombination aus n-acetylcystein und levulose zur verhütung des zelltods und verwandter erkrankungen
AT97920756T ATE222496T1 (de) 1996-05-16 1997-05-13 Pharmakologische kombination aus n-acetylcystein und levulose zur verhütung des zelltods und verwandter erkrankungen
EP97920756A EP0839534B1 (en) 1996-05-16 1997-05-13 Pharmacological association between n-acetylcystein and levulose for preventing cellular death and related diseases
PT97920756T PT839534E (pt) 1996-05-16 1997-05-13 Associacao farmacologica entre n-acetilcisteina e levulose para prevencao da morte celular e doencas relacionadas
DK97920756T DK0839534T3 (da) 1996-05-16 1997-05-13 Farmakologisk kombination af N-acetylcystein og levulose til forebyggelse af celledød og relaterede sygdomme
US09/007,071 US5962421A (en) 1996-05-16 1998-01-14 Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09601091A ES2114817B1 (es) 1996-05-16 1996-05-16 Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas.

Publications (2)

Publication Number Publication Date
ES2114817A1 ES2114817A1 (es) 1998-06-01
ES2114817B1 true ES2114817B1 (es) 1999-02-16

Family

ID=8294833

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09601091A Expired - Fee Related ES2114817B1 (es) 1996-05-16 1996-05-16 Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas.

Country Status (7)

Country Link
EP (1) EP0839534B1 (es)
AT (1) ATE222496T1 (es)
DE (1) DE69714821T2 (es)
DK (1) DK0839534T3 (es)
ES (1) ES2114817B1 (es)
PT (1) PT839534E (es)
WO (1) WO1997042961A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819616A1 (de) * 1998-05-04 1999-11-11 Hexal Ag Verwendung von Antioxidantien zur Behandlung von entzündlichen Hauterkrankungen
IT1312086B1 (it) * 1999-04-21 2002-04-04 Zambon Spa Uso della nac per la preparazione di un medicamento adatto allasomministrazione endovenosa per la prevenzione dello stress
FR2815042B1 (fr) * 2000-10-06 2005-01-07 Haguenauer Odile Cohen Utilisation d'une composition a activite antioxydante pour le conditionnement de cellules souches

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
IT1217445B (it) * 1988-04-29 1990-03-22 Altergon Sa Composizione farmaceutiche orosolubili contenti acetilcisteina
DE4134723C1 (es) * 1991-10-21 1993-02-11 Pfrimmer Kabi Gmbh & Co Kg, 8520 Erlangen, De
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making

Also Published As

Publication number Publication date
WO1997042961A1 (es) 1997-11-20
DE69714821T2 (de) 2003-04-10
PT839534E (pt) 2002-12-31
ES2114817A1 (es) 1998-06-01
DK0839534T3 (da) 2002-12-23
DE69714821D1 (de) 2002-09-26
ATE222496T1 (de) 2002-09-15
EP0839534B1 (en) 2002-08-21
EP0839534A1 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
PA8464901A1 (es) Procesos para la sintesis de 1,3-dioles
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
PT735890E (pt) Misturas de 2',3'-didesoxi-inosina e hidroxicarbamida para inibicao da disseminacao retroviral
CO4440626A1 (es) Amidas terapeuticas
PT907652E (pt) Compostos e processos imunossupressores
MX9305248A (es) Compuestos de diarilpiperazinoacetamida.
ATE206916T1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
FR2662698B1 (es)
ATE160561T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
DE69123363D1 (de) Neue zusammensetzungen
ES2114817B1 (es) Asociacion farmacologica entre n-acetilcisteina y levulosa para la prevencion de la muerte celular y enfermedades asociadas.
ES2166900T3 (es) Derivados de ara-c.
ES2106584T3 (es) Fijacion de picaportes giratorios.
PT1056754E (pt) Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
RU2001120358A (ru) Применение ингибиторов натрий-водород-антипортера для получения лекарственного средства для ингибирования обусловленных возрастом дисфункций органов, обусловленных возрастом заболеваний и для продления жизни
ATE168988T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
ES539777A0 (es) Procedimiento para la produccion de indolofenantridinas
ES2174101T3 (es) Articulo absorbente con elemento absorbente estabilizante.
CA2294482A1 (en) Treatment of aging skin
ZA969351B (en) Organic compositions
AR029307A1 (es) Composicion para la estimulacion de la sintesis del pigmento melanico y procedimiento para su obtencion
TR199701605A2 (xx) S�lfonamid-substit�e edilmi� bile�ikler

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19980601

Kind code of ref document: A1

Effective date: 19980601

FD1A Patent lapsed

Effective date: 20060517